EMA recommends four new generics Posted 21/02/2020

At the Committee for Medicinal Products for Human Use’s (CHMP) January 2020 meeting, the Committee recommended four new generics, and one new biosimilar, for approval.
The European Medicines Agency’s (EMA) latest CHMP meeting took place 27−30 January 2020.
At the meeting, the CHMP recommended a total of 15 medicines for approval, including four generic medicines:
The Committee also recommended one new biosimilar: All of the recommended drugs are awaiting European Commission approval for launch.
Related articles
3979C Generics applications under review by EMA – January 2020
At the meeting, the CHMP recommended a total of 15 medicines for approval, including four generic medicines:
The Committee also recommended one new biosimilar: All of the recommended drugs are awaiting European Commission approval for launch.
Related articles Generics applications under review by EMA – January 2020 Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.
Azacitidine betapharm (azacytidine), from betapharm Arzneimittel GmbH, for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Azacitidine Mylan (azacitidine), from Mylan, for the same indications
Arsenic trioxide Mylan (arsenic trioxide), also from Mylan, for the treatment of acute promyelocytic leukaemia
Cinacalcet Accord Pharma (cinacalcet), from Cinacalcet, for the treatment of secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism
Ruxience (rituximab), from Pfizer, for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and Pemphigus vulgaris
3983D EMA approval for rituximab biosimilar Ruxience
http://www.gabionline.net/Biosimilars/News/EMA-approval-for-rituximab-biosimilar-Ruxience
http://www.gabionline.net/Generics/General/Generics-applications-under-review-by-EMA-January-2020
The European Medicines Agency’s (EMA) latest CHMP meeting took place 27−30 January 2020.
• Azacitidine betapharm (azacytidine), from betapharm Arzneimittel GmbH, for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
• Azacitidine Mylan (azacitidine), from Mylan, for the same indications
• Arsenic trioxide Mylan (arsenic trioxide), also from Mylan, for the treatment of acute promyelocytic leukaemia
• Cinacalcet Accord Pharma (cinacalcet), from Cinacalcet, for the treatment of secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism
• Ruxience (rituximab), from Pfizer, for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and Pemphigus vulgaris
EMA approval for rituximab biosimilar Ruxience
Comments (0)
Generics News Research General
- The role of authorized generics in Improving a...Generics/Research | Posted 05/03/2021
- Opportunities for generics with Korean patent e...Generics/General | Posted 05/03/2021
- Approving generics of polymer-based parenteral...Generics/Research | Posted 26/02/2021
- AIFA updates the Transparency Lists for genericsGenerics/General | Posted 26/02/2021
Biosimilars News Research General
- Biosimilar patent litigation trends in the USBiosimilars/General | Posted 05/03/2021
- Biosimilars approved in the USBiosimilars/General | Posted 14/08/2015
- Different approaches to the interchangeability...Biosimilars/Research | Posted 05/03/2021
- Efficacy and safety of interferon beta-1a (Reci...Biosimilars/Research | Posted 05/03/2021